Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 5CNS 3Plasma cell 2Other solid neoplasm 2Breast 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Recurrence 1Neuroblastoma 1Neoplasms 1Lymphoma 1Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 166Magnetic Resonance Spectroscopy 131Radiotherapy 97Specimen Handling 81Radiosurgery 61Cyclophosphamide 56pembrolizumab 52Bevacizumab 52Radiation 48Nivolumab 48Carboplatin 36Biopsy 33Irinotecan 29Etoposide 25Vincristine 24Lomustine 24Topotecan 23Ipilimumab 23Blood Specimen Collection 23Cisplatin 22dinutuximab 21fludarabine 19Surgical Procedures, Operative 19Radiotherapy, Intensity-Modulated 19X-Rays 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pharmaceutical Preparations × CNS × 1 year × Clear all
NCT07431216 2026-03-30

A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression

Starlight Therapeutics Inc.

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Glioblastoma

NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT07334301 2026-01-12

BEACON2

University of Birmingham

Phase 1/2 Recruiting
160 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡